Objective Systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are related chronic autoimmune diseases of complex aetiology in which the interferon (IFN) pathway plays a key role. Recent studies have reported an association between IRF7 and SLE which confers a risk to autoantibody production. A study was undertaken to investigate whether the IRF7 genomic region is also involved in susceptibility to SSc and the main clinical features. Methods Two case-control sets of Caucasian origin from the USA and Spain, comprising a total of 2316 cases of SSc and 2347 healthy controls, were included in the study. Five single nucleotide polymorphisms (SNPs) in the PHRF1-IRF7-CDHR5 locus were genotyped using TaqMan allelic discrimination technology. A meta-analysis was performed to test the overall effect of these genetic variants on SSc.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic fi brotic autoimmune disease in which autoantibodies against several nuclear and/or nucleolar antigens are commonly produced; however, each SSc-associated antibody specifi city tends to be mutually exclusive in distinct clinical subsets of the disease. Thus, they are important diagnostic and prognostic markers in clinical practice. Although antinuclear autoantibodies are detected in different connective tissue autoimmune diseases, SSc shows its own particular autoantibody profi le that tends not to overlap with that of other related diseases. In SSc the two major subclasses of specifi c autoantibodies are the anticentromere autoantibodies (ACA), which are related to limited skin involvement and an increased risk of pulmonary arterial hypertension, and the antitopoisomerase autoantibodies (ATA), which confer susceptibility to diffuse skin and pulmonary fi brosis with an increased mortality. [1] [2] [3] SSc has a complex aetiology with multiple susceptibility genes interacting for the development of the disease in concert with epigenetic and environmental factors. It is likely that an imbalance between risk and protective loci is a key factor contributing to the predisposition and clinical phenotype of SSc. 4 Recent candidate gene and genomewide association studies (GWAS) have identifi ed several markers that are clearly associated with SSc. 5 Noteworthy are the associations reported for STAT4 and IRF5, since polymorphisms of these genes showed the strongest signals outside the HLA region in a recent GWAS of SSc. 6 These two genes are representative regulators in the interferon (IFN) pathway, which comprise a large number of cytokines with different modulatory effects on innate and adaptive immunity. In this regard, type I IFNs were reported to have a central aetiopathogenic role in the development and progression of systemic lupus erythematosus (SLE). 7 Interestingly, a type I IFN signature similar to that described in SLE has also been observed in microarray analyses of peripheral blood and skin cells of patients with SSc. 8 9 Interferon regulatory factor 7 (IRF7) has recently been described as a susceptibility locus for SLE. [10] [11] [12] This gene encodes a member of the IFN regulatory transcription factor family, which plays a key role in the IFN-inducible pathway by activating type I IFN genes in response to viral infection or DNA/ RNA-containing immune complexes. 13 Novel identifi cation of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis crucial for appropriate IFN-mediated physiological functions. 14 Taking into account the genetic similarities between SSc and SLE, 4 9 15 we aimed to investigate whether variation within this genomic region is also involved in SSc susceptibility and/or its major clinical and autoantibody manifestations.
METHODS

Study population
Two independent Caucasian populations, a discovery cohort from the USA and a replication cohort from Spain, were analysed in this study, comprising a total of 2316 SSc cases and 2347 unrelated healthy individuals recruited in the same geographical areas and matched by age, sex and ethnicity. The US cohort was composed of 1282 cases of SSc and 875 controls. Samples from patients in the USA came from the Scleroderma Registry and DNA Repository, Genetics versus Environment in Scleroderma Outcomes Study (GENISOS) and the rheumatology divisional collection evaluated at the University of Texas Health Science Center at Houston. The Spanish cohort consisted of 1034 cases of SSc and 1472 controls from previously established collections with nationally representative recruitment. Clinical features of the patients from both cohorts are summarised in table 1.
All patients with SSc fulfi lled the 1980 American College of Rheumatology classifi cation criteria for this disease 16 or had at least three of the fi ve CREST (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias) features. 17 Case sets were further subdivided based on their skin involvement into limited cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma (dcSSc) subgroups, 18 and by autoantibody status according to the presence of ACA or ATA. ACAs were determined by their characteristic distinctive pattern on HEP 2 cells, and ATAs were detected by passive immunodiffusion against calf thymus extract (Inova Diagnostics, Davis, California, USA).
SNP selection and genotyping
Four single nucleotide polymorphisms (SNPs), rs12286521, rs4963128, rs702966 and rs2246614, which span a 48 kb genomic region including PHD and ring fi nger domains 1 (PHRF1, also known as KIAA1542), cadherin-related family member 5 (CDHR5) and IRF7 genes were selected to tag haplotype blocks present in the CEU HapMap reference dataset, as described previously. 10 A fi fth SNP within the IRF7 gene, rs1131665, was also included in the study because it produces a non-synonymous change in the DNA sequence (Q412R) and has recently been associated with SLE susceptibility. 11 Genomic DNA was extracted from peripheral white blood cells following standard procedures. Samples were genotyped for the above PHRF1-IRF7-CDHR5 genetic variants using TaqMan 5' allele discrimination assays (rs12286521, rs4963128, rs702966 and rs2246614 were predesigned assays with IDs: C_26650291_10, C_1611594_10, C_7470754_10 and C_16061601_10, and rs1131665 was designed as a custom assay) in a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, California, USA).
Statistical analysis
The statistical power of the combined analysis was >99% for all the SNPs to detect associations with OR=1.3 at the 5% signifi cance level, according to Power Calculator for Genetic Studies 2006 software which uses the methods described by Skol et al. 19 All statistical analyses of the allele frequencies were carried out using the Linux software PLINK V.1.07 (http://pngu.mgh. harvard.edu/purcell/plink/). 20 To test for association, 2 × 2 contingency tables and χ 2 and/or Fisher exact tests, when appropriate, were used to calculate p values. OR and 95% CIs were obtained according to the Woolf method. Mantel-Haenszel tests under fi xed effects or random effects (DerSimonian-Laird), when necessary, were performed to submit the combined data to meta-analysis and the Breslow-Day method was used to estimate the homogeneity among the two cohorts. The Benjamini and Hochberg step-up false discovery rate (FDR) control correction 21 for multiple testing was applied to the p values in the analyses of the discovery cohort and in the combined meta-analyses; p values <0.05 were considered statistically signifi cant.
Dependency of association between each SNP and every studied genetic variant was determined by conditional logistic regression analysis as implemented in PLINK. We also analysed the different allelic combinations using PLINK and Haploview (V.4.2). 22 Allelic combinations with a frequency <5% in control groups were excluded from the analysis. Meta-analyses of the different allelic combinations were performed using PLINK and StatsDirect V.2.6.6 (StatsDirect, Altrincham, UK).
RESULTS
In all cohorts the genotyping success rate was >95% and there was no signifi cant departure from Hardy-Weinberg equilibrium at the 5% signifi cance level. In addition, control allelic frequencies of rs4963128, rs702966, rs1131665 and rs12286521 were similar to those reported for the CEU population in the HapMap project (http://hapmap.ncbi.nlm.nih.gov/). The genetic variant rs1131665 was not genotyped in HapMap; however, the minor allele frequency that we have observed for this SNP in the control population is in agreement with previous published data. 11 
Independent analyses
We fi rst investigated whether these fi ve representative polymorphisms within the genomic region around the IRF7 locus were associated with SSc and clinical/autoantibody phenotypes in a large Caucasian US cohort (see table S1 in online supplement). This preliminary analysis showed signifi cant differences in allele frequencies between the ACA-positive subgroup and the control set for rs1131665 (p FDR =3.09 × 10 −3 , OR=0.70, CI 95% 0.57 to 0.87), rs702966 (p FDR =3.09 × 10 −3 , OR=0.71, CI 95% 0.58 to 0.88), rs4963128 (p FDR =0.028, OR=0.79, CI 95% 0.65 to 0.96) and rs2246614 (p FDR =0.046, OR=0.82, CI 95% 0.68 to 0.99). To further explore the possible involvement of the IRF7 region in ACA susceptibility, a second large and well-defi ned Caucasian cohort from Spain was genotyped (see table S2 in online supplement). Three of 
Meta-analysis
Since no heterogeneity of the ORs among the US and Spanish populations was observed, a combined meta-analysis was performed to increase the statistical power and hence to obtain more accurate estimates of susceptibility ( On the other hand, rs4963128 showed a weak association with dcSSc (p FDR = 0.034, OR= 0.84, CI 95% 0.74 to 0.95) and trends of association were observed in the rest of the subtype analyses for these SNPs. However, the statistical signifi cance was lost when the ACA-positive patients were excluded from all the above analyses, suggesting that these associations rely on ACA positivity.
Additionally, to obtain further evidence of the association between the IRF7 region and ACA production, we compared 
Conditional logistic regression
The linkage disequilibrium (LD) analysis showed that rs702966 was in almost complete LD with the non-synonymous IRF7 SNP rs1131665 in the studied populations (r 2 =0.93 in the USA and 0.97 in Spain). It was therefore not possible to determine whether one of these two genetic variants had an independent effect of the haplotype background. However, pairwise conditioning showed that the association of rs2246614 with the presence of ACA could be explained by those of rs1131665/ rs702966 and rs4963128, since the latter SNPs remained significant when conditioned to rs2246614, taking into account the two populations as covariate (table 3) . Nevertheless, we could not establish whether the rs1131665 and rs4963128 signals were independent.
Allelic combinations
We performed several allelic combination tests to analyse the possible interaction between the SNPs of this genomic region. Our results indicated that the association with the presence of ACA could be narrowed down to allelic combinations of the two most associated SNPs, rs4963128 and rs1131665 (table 4) , as none of the remaining allelic combinations between the four associated SNPs increased their statistical signifi cance (see table S4 in online supplement). However, the strength of the ACA association observed in the allelic combinations was not higher than that observed for rs4963128 and rs1131665 in the independent analysis (table 2) .
DISCUSSION
IRF7 has been shown to be a master factor in the transcriptional activation of type I IFN genes which encode proteins that are key regulators of the immune system. 13 Upregulated expression levels of type I IFN-inducible genes in peripheral blood cells have been correlated with increased disease activity and specifi c autoantibody profi les in patients with SLE. [23] [24] [25] Recent studies have also shown a dysregulation of the type I IFN pathways in patients with SSc compared with healthy controls. [26] [27] [28] [29] In this regard, it is likely that type I IFN molecules increase the infl ammatory potential of dermal fi broblasts through the upregulation of Toll-like receptors. 30 In addition, several genetic variants in the IFN pathway, including polymorphisms within IRF5 and STAT4 loci, have been reported to be associated with both SLE and SSc susceptibility. 6 31 Hence, it is likely that the presence of a type I IFN signature is also of special relevance in the pathophysiology of SSc.
Despite the fact that no functional or mechanistic data have been obtained, which is certainly an important limitation of this study, our results clearly indicate that the IRF7 genomic region is a susceptibility locus for SSc and may confer disease risk through a role in ACA production. This is supported by the fact that the statistical signifi cance observed when the global disease and the limited/diffuse subsets were tested was lost when the ACA-positive patients were removed from the analyses. Four of the fi ve polymorphisms analysed showed strong evidence of association with ACA production. In relation to rs2246614, this genetic variant is specifi cally located within the IRF7 adjacent gene CDHR5, a novel mucin-like gene member of the cadherin superfamily whose specifi c function has not yet been determined. 32 Interestingly, rs2246614 corresponds to a non-synonymous modifi cation (R357S), although its possible functional implication is still unknown. Our logistic regression data indicate that this SNP may be tagged by rs1131665 and/or rs4963128. However, since the remaining p values of the latter variants were weak after the analysis, further studies should be carried out to investigate whether CDHR5 rs2246614 is indeed involved in SSc susceptibility or simply refl ects association signals within IRF7.
In relation to the analysed IRF7-PHRF1 genetic variants, rs4963128 and rs702966 were highly associated with the presence of ACA in our study. Interestingly, GWAS data showed a strong association between rs4963128 and SLE, 15 and subsequent studies suggested that this association is probably specifi c for autoantibody production. 10 12 On the other hand, the group.bmj.com on March 27, 2012 -Published by ard.bmj.com Downloaded from 3'-untranslated region PHRF1 SNP rs702966 was also found to be associated with the presence of anti-double-stranded DNA (anti-dsDNA) antibodies in patients with SLE. 10 Owing to the LD structure of the PHRF1-IRF7 genomic region, the associations of both SNPs-which are located 23 kb and 0.6 kb telomeric to IRF7, respectively-have been proposed to be representative of the SLE association signals within the IRF7 gene. 11 15 33 Moreover, autoantibody-positive SLE patients carrying rs4963128 and/or rs702966 risk genotypes exhibited increased serum levels of IFNα, 10 thus suggesting that these polymorphisms may be tagged by a causal IRF7 SNP. Supporting this notion, the analysis of the LD structure of our cohorts showed that rs1131665 is in strong LD with s4963128 and in nearly complete LD with rs702966. This strong correlation between the alleles of these SNPs made it impossible to discern the true susceptibility variant. Nevertheless, we speculate that the best candidate should be rs1131665, since it produces a non-synonymous change (Q412R) located in exon 5 of the IRF7 gene. It has been reported that the risk allele of this SNP leads to increased activation of IRF7 in vitro, correlated with SLE susceptibility in populations of different ethnicity. 11 This functional IRF7 variant showed the highest association signal with ACA production in our meta-analysis, and the genetic combinations that were associated with ACA susceptibility did not reach higher statistical signifi cance than that observed in the independent analysis of rs1131665. The LD pattern of rs1131665 is not yet clear because it was not genotyped in the reference population of the HapMap project. However, since this IRF7 variant has been shown to have functional consequences in the downstream interferon pathway, it may represent the causal SNP of this association. In any case, this genomic region should be analysed in more detail to determine defi nitively whether rs1131665 is the tagger SNP or whether there are other independent signals.
In summary, together with previous fi ndings, [26] [27] [28] [29] [30] our results strongly suggest that the IRF7 genomic region plays an important role in ACA production among patients with SSc. The fact that this same locus is also associated with a specifi c autoantibody (dsDNA) in SLE 10 12 indicates that common immunological pathways may underlie both diseases. Supporting this idea, previous studies have reported that SLE showed the strongest familial accumulation in patients with SSc and that ACA positivity was associated with polyautoimmunity in SSc families. 34 However, the main limitation of this study is the lack of functional data that would be essential for a better understanding of how IRF7 leads to a specifi c autoantibody profi le in autoimmunity. More comprehensive studies therefore need to be performed to elucidate the causal polymorphism(s) of this association and to identify the molecular mechanisms involved in the production of autoantibodies, with the aim of developing more effective therapeutic strategies in autoimmune diseases.
